Dietary intake of phytoestrogens and the risk of bladder cancer in the PLCO Screening Trial
Principal Investigator
Name
yadong Li
Degrees
M.M
Institution
The Second Affiliated Hospital of chongqing medical university
Position Title
Dr
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-1261
Initial CDAS Request Approval
Jun 22, 2023
Title
Dietary intake of phytoestrogens and the risk of bladder cancer in the PLCO Screening Trial
Summary
Bladder cancer (BCa) is one of the most frequently diagnosed malignancies in urology, with 573,278 newly diagnosed cases and 212,536 deaths worldwide in 2020 [1]. Men exhibited around 4-fold higher incidence than women to develop bladder cancer. Apart from the risk factors such as smoking and occupational exposure to aromatic amines, there is insufficient evidence regarding risk factors in relation to bladder cancer. To reduce the incidence and mortality of this bladder cancer, it is vitally important to identify more altered risk factors in epidemiological studies, especially prospective cohort studies.
Phytoestrogens are a kind of estrogen-like bioactive compounds originated from plants. Individual phytoestrogens derived from dietary sources are classified into three major categories: isoflavones (e.g., genistein, daidzein, glycitein, for- mononetin and biochanin A), lignans (e.g., matairesinol and seco-isolariciresinol) and coumestans (e.g., coumestrol) [2]. The occurrence and development of bladder cancer may be closely related to sex hormones. Isoflavones are principle classes, which have antioxidative, anti-inflammatory, and anti-cancer properties in animal models. Moreover, phytoestrogen intake may modulate the incidence of certain types of cancer because their structural similarity to 17 β-estradio resulted in competitive binding to estrogen receptors. Some studies had reported that ERβ could interact with the promoter region of FOXO1, a transcription factor identified as a suppressor of bladder cancer [3]. A population-based prospective study in Japan showed that men with higher intakes of isoflavones had a decreased risk of bladder cancer [4]. However, no prospective multicenter cohort accurately evaluated this potential association in USA. Hence, we sought to investigate this potential association in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
References:
1. Sung H, Ferlay J, Siegel RL, et.al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71(3):209-49.
2. Rietjens, I.M.C.M, Louisse J, Beekmann K. The potential health effects of dietary phytoestrogens. Br J Pharmacol, 174(11), 1263-1280.
3. Ide H, Mizushima T, Jiang G et al: FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells. Endocrine-related cancer 2020, 27(4):231-244.
4. Wada KT, Michiko T, Takashi T et al. Soy Isoflavone Intake and Bladder Cancer Risk in Japan: From the Takayama Study.[J] .Cancer Epidemiol Biomarkers Prev, 2018, 27: 1371-1375.
Phytoestrogens are a kind of estrogen-like bioactive compounds originated from plants. Individual phytoestrogens derived from dietary sources are classified into three major categories: isoflavones (e.g., genistein, daidzein, glycitein, for- mononetin and biochanin A), lignans (e.g., matairesinol and seco-isolariciresinol) and coumestans (e.g., coumestrol) [2]. The occurrence and development of bladder cancer may be closely related to sex hormones. Isoflavones are principle classes, which have antioxidative, anti-inflammatory, and anti-cancer properties in animal models. Moreover, phytoestrogen intake may modulate the incidence of certain types of cancer because their structural similarity to 17 β-estradio resulted in competitive binding to estrogen receptors. Some studies had reported that ERβ could interact with the promoter region of FOXO1, a transcription factor identified as a suppressor of bladder cancer [3]. A population-based prospective study in Japan showed that men with higher intakes of isoflavones had a decreased risk of bladder cancer [4]. However, no prospective multicenter cohort accurately evaluated this potential association in USA. Hence, we sought to investigate this potential association in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
References:
1. Sung H, Ferlay J, Siegel RL, et.al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71(3):209-49.
2. Rietjens, I.M.C.M, Louisse J, Beekmann K. The potential health effects of dietary phytoestrogens. Br J Pharmacol, 174(11), 1263-1280.
3. Ide H, Mizushima T, Jiang G et al: FOXO1 as a tumor suppressor inactivated via AR/ERβ signals in urothelial cells. Endocrine-related cancer 2020, 27(4):231-244.
4. Wada KT, Michiko T, Takashi T et al. Soy Isoflavone Intake and Bladder Cancer Risk in Japan: From the Takayama Study.[J] .Cancer Epidemiol Biomarkers Prev, 2018, 27: 1371-1375.
Aims
To investigate the prospective associations between intake of phytoestrogens and risk of bladder cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
Collaborators
(1) Chuan Liu, Department of urology , the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.
(2) Zheng-Ju Ren, Department of urology , the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China.